Acetyl-11-Keto-β-Boswellic Acid Accelerates the Repair of Spinal Cord Injury in Rats by Resisting Neuronal Pyroptosis with Nrf2

This study investigates the potential of Acetyl-11-keto-β-boswellic acid (AKBA) in reducing neuronal damage caused by spinal cord injury. The study found that AKBA can mitigate the release of IL-18 and IL-1β, reducing neuronal loss and speeding up recovery from spinal cord injury. The research used rats with spinal cord injuries, dividing them into groups to receive AKBA treatment or a control. The investigation revealed that AKBA suppresses the expression of Caspase-1, a protein that initiates pyroptosis, thereby lessening the release of GSDMD and alleviating pyroptosis. The experiments included assessing neuronal damage, measuring inflammation, and using advanced techniques to understand how AKBA affects the spinal cord at a molecular level. The results suggest that AKBA can reduce spinal cord neuronal apoptosis, which provides evidence for AKBA's potential as a treatment for spinal cord injury.

• 1
  AKBA reduces the expression of the pyroptotic initiator protein Caspase-1 by engaging the Nrf2-ROS-NLRP3 pathway, thus mitigating pyroptosis.
• 2
  AKBA demonstrates the ability to attenuate the release of IL-18 and IL-1β, which curbs neuronal loss and expedites the restorative processes within spinal cord injury context.
• 3
  In vitro, AKBA reduces LDH release and ROS generation in a spinal neuronal pyroptosis model, suggesting a protective effect on neuronal cell membranes and oxidative stress.